logo
Minnetrista mom of 3 uses data and science through Edina lab to improve her life

Minnetrista mom of 3 uses data and science through Edina lab to improve her life

CBS News15 hours ago
The beginning of August is peak training season for the Twin Cities Marathon. One participant of this year's race is a mom of three from Minnetrista, Minnesota, who is taking extra steps to make sure she's running her best and in the safest way.
"I had my third baby. I wasn't feeling good," said Valerie Vadnais Wall. "I was tired all the time taking care of everybody else and not myself."
She's been running for the last 10 years, and has seen huge improvement in her health.
"I've lost 65 pounds," said Vadnais Wall.
She loved running so much that she joined a group of women in the Chaska/Chanhassen community to keep her motivated.
"I decided that I want to have fun and join something that is empowering, and it was Mom's On The Run," said Vadnais Wall.
Now, she's preparing for her fourth marathon, which is taking place in the Twin Cities, and has decided to take her training to the next level. As a dentist who co-owns a practice, she believes in the science and importance of data.
"I don't want to succumb to the health diseases, like diabetes, high blood pressure. My mom has dementia, and I didn't want that for myself, so I wanted to take the power to have the data and then to do better," said Vadnais Wall, who came to Kelly McKenzie at the Human Powered Health lab in Edina, Minnesota.
"It's nice to have data to validate what you're doing is working for you," said McKenzie.
At the lab, McKenzie measures her oxygen levels, heart rate, bone strength and balance.
"For her going into premenopause, and then menopause eventually, you want to make sure that your bone is in a really healthy spot, so that when your estrogen starts to decrease, your bone will naturally go with it," said McKenzie.
This type of testing is not reserved for elite athletes. It's recommended for everyone seeking to further their knowledge on their health and well-being.
"I'm not a professional athlete, so it's a little intimidating, but [Kelly] made it super easy and comfortable, and I'm excited to know that all this hard work is paying off," said Vadnais Wall.
This type of testing will help Vadnais Wall with basic things outside of running, like lifting groceries and walking up stairs, to avoid any injuries.
"I do feel that, at 51, I'm in the best shape of my life, even after my 20s and 30s, so I'm excited," said Vadnais Wall. "I do want to be that role model to other people, to other women who are middle-aged."
Vadnais Wall will be running the Twin Cities Marathon on Oct. 5 with her kids cheering her on along the course.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Orforglipron: A Pill Alternative to GLP-1 Injections
Orforglipron: A Pill Alternative to GLP-1 Injections

Medscape

time3 minutes ago

  • Medscape

Orforglipron: A Pill Alternative to GLP-1 Injections

This transcript has been edited for clarity. Orforglipron is a once-daily, oral, nonpeptide GLP-1 receptor agonist currently under investigation for the treatment of both obesity and type 2 diabetes. The most recent weight management data come from a phase 2 trial of 272 adults with a BMI over 30, or over 27 and at least one weight-related medical condition, but without received daily orforglipron at one of four doses or placebo for 36 weeks. The average baseline BMI was 37.9. At 36 weeks, participants on the highest dose of orforglipron (45 mg) lost an average of 14.7% of their total body weight compared to 2.3% with placebo. Weight loss of at least 10% occurred in 46% to 75% of participants on orforglipron versus 9% on placebo, and 48% of participants on 45 mg lost 15% or more of their total body weight. It's important to note that this trial was only 36 weeks long and that weight loss had not yet plateaued, which suggests the possibility of additional weight loss with longer treatment. There were also improvements in weight-related and cardiometabolic parameters. The most common side effects were mild to moderate [gastrointestinal] symptoms, which mainly occurred during dose the safety profile of orforglipron was consistent with that of the other GLP-1 receptor agonists. Orforglipron is currently in phase 3 ATTAIN trials for obesity, with results expected in late 2025. Eli Lilly plans to seek FDA approval for weight management by the end of 2025. If approved, orforglipron would offer an oral, incretin-based alternative with efficacy potentially similar to the injectable GLP-1s, helping to improve treatment adherence and access. Top-line results from the phase 3 ACHIEVE-1 trial for orforglipron for type 2 diabetes were published in April. The full results were presented at the [American Diabetes Association] conference in June and published soon after. Eli Lilly expects to submit for approval for the treatment of type 2 diabetes in 2026.

Linda Yaccarino joins health tech platform eMed as CEO after leaving X
Linda Yaccarino joins health tech platform eMed as CEO after leaving X

TechCrunch

time34 minutes ago

  • TechCrunch

Linda Yaccarino joins health tech platform eMed as CEO after leaving X

Linda Yaccarino's next role after departing X as CEO will be another chief executive role at eMed Population Health, an AI startup building a tech platform for patients using GLP-1s. Yaccarino was a longtime advertising executive at NBCUniversal, but left to join X as CEO for two years, where she managed to have a positive impact on the social network's troubled ad revenue model, despite her and Elon Musk's shared approach to minimizing content moderation. Though Yaccarino does not have experience in health tech, eMed said in a press release that they sought her out for her 'undeniable ability to negotiate new partnerships' — it certainly also helps that her tenure at X made her well-known in the tech world, drawing more eyes toward the startup. eMed previously produced a tech platform that was designed to be used with at-home COVID-19 rapid antigen tests, guiding users through the process of administering these tests properly. Now, eMed is focused on GLP-1s, the class of drugs like Ozempic, which can be used for both weight management and treatment of type II diabetes. 'To be a leader in today's healthcare marketplace, companies need to have a fearless tenacity that allows them to not only grow, but to also be brave enough to step forward and redefine an entire industry,' Yaccarino said in a press release. 'We are very well-positioned to be that tenacious leader, striving toward our ultimate goal of improving global healthcare outcomes through our groundbreaking services and platforms.'

From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health
From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health

Yahoo

timean hour ago

  • Yahoo

From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health

Fellow Health just raised $24 million in a Series B funding round, bringing its cash haul across multiple offerings to $48 million. The San Leandro, California startup advances male reproductive health through "patient-centric testing solutions" and plans to use the capital infusion to expand its mail-in semen analysis services. Fellow Health provides clinical grade, mail-in analysis of male fertility and post-vasectomy status while committing to "privacy, convenience and timely results." Italready has a network of more than 2,500 fertility and urology providers nationwide and wants to "deepen its footprint" through expansion into employer-sponsored fertility benefits and "broader access initiatives." Don't Miss: The same firms that backed Uber, Venmo and eBay are investing in this pre-IPO company disrupting a $1.8T market — Accredited Investors: Grab Pre-IPO Shares of the AI Company Powering Hasbro, Sephora & MGM— led the latest funding round, in which asset management firm Forest Road participated for the first time. Forest Managing Partner of Life Sciences Bill Burkoth will join Fellow's board as part of the financing deal. Other investors since the initial round include Labcorp Venture Fund, Genoa Ventures and Mantis Venture Capital. "Fellow Health is exactly the kind of company we look for – operating in a large, overlooked market that's long overdue for disruption," Burkoth said in a statement. "With over 50,000 test results delivered so far this year, they've proven there is real demand for a better patient experience." Live sperm gets counted in fertility analysis. These cells can live three to days within the cervix, uterus and fallopian tubes, but usually die in under an hour outside a woman's body. The mail-in service addresses this time bomb with a "preservation solution designed to stabilize your sample and a gel pack that helps maintain a moderate temperature during transit." Mail-in post-vasectomy testing is less time critical because it counts both living and dead sperm. Trending: 'Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can Fellow Health points to studies backing up its claim that it can provide "results on par with traditional one-hour semen analysis when analyzing samples received within 52 hours of when they were produced." It sells both testing products and a cryopreservation service without a doctor's prescription at its website. 'Male reproductive health should not be reactive or inaccessible,' Fellow CEO Brian Hogan said in the statement. 'We are on track to deliver over 40% year-over-year revenue growth, with a path to profitability in our fertility segment by 2026. This investment allows us to scale that vision and support both patients and providers with modern tools that work.'However, Fellow Health faces stiff competition in the male fertility space that could impact this optimistic revenue outlook. Rival Posterity Health booked $13 million in Series A funding earlier this year. The company partnered with Mark Cuban Cost Plus Drug Company in 2023 to provide access to treatments for infertility, sexual dysfunction and low testosterone. A year earlier, American telehealth provider Ro bought Dadi, another male fertility and sperm testing startup. Its reproduction preservation service for men looks like a direct competitor to Fellow Health's family of products. Ro has also made a splash in women's health, acquiring Modern Fertility in 2021. Read Next: Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." Image: Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? APPLE (AAPL): Free Stock Analysis Report TESLA (TSLA): Free Stock Analysis Report This article From Taboo To Tech: Fellow Health's $24M Raise Signals Big Shift In Men's Reproductive Health originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store